226 days ago
In his article yesterday about Tern (TERN) Nigel highlighted Wyld’s weasel words that “the company expects to have sufficient funds to meet its obligations throughout 2023”. If Wyld’s accounts were prepared under IFRS accounting standards or if Wyld were listed on a “Recognised” Swedish stock exchange which would require the use of IFRS, it would not be able to get away with such weasel words but Wyld uses “Swedish Accounting Standards Board’s general guidelines BFNAR 2012:1 Annual Accounts and Consolidated Financial Statements”.
1998 days ago
Following the recent placing, the house - thus not impartial - broker VSA has rejigged ita valuation for Columbus Energy (CERP) in the detailed note below. The price target comes down from 25p to 21.4p to reflect the dilution but at 3.7p the stance remains buy. I agree with the conclusion but am not so sure that the price target is not a tad ambitious.
2708 days ago
Amryt Pharma (AMYT) has announced that it has secured a €20m debt facility from the European Investment Bank on, what broker Stifel says, are very attractive commercial terms. Stifel says that the facility will not only extend the company's funding until well into 2019, but also provide funding for development of acromegaly product AP102 and potential launch funding for Episalvan in partial thickness wounds. Stifel concludes that the shares are a buy at 14p with a price target of 49p. Yes indeed. Since we own the shares I thought we'd share the note with you.
